Get startedLog in
    Picture of Cellectis SA logo

    ALCLS — Cellectis SA News Story

    0.000.00%
    fr flag iconLast trade - 00:00
    HealthcareHighly SpeculativeSmall CapSucker Stock
    All News

    France's Cellectis swings to net loss in Q4

    Picture of Cellectis SA logoCellectis SA
    20/03/2026 24:09
    Overview

France biotechnology firm's Q4 revenue declined yr/yr; reports net loss vs. year-ago profit

Annual revenue rose sharply, driven by AstraZeneca collaboration activities

Company ended 2025 with $211 mln cash, providing runway into H2 2027

Outlook

Cellectis expects interim Phase 2 lasme-cel data in r/r B-ALL in Q4 2026

Company anticipates submitting BLA for lasme-cel in 2028

Company expects cash position to fund operations into H2 2027

Result Drivers

HIGHER R&D COSTS - Co said R&D expenses rose in 2025 mainly due to increased personnel costs and higher stock-based compensation

NET FINANCIAL LOSS - Co said net financial loss for the year reflected higher foreign exchange losses and changes in fair value of financial instruments

Company press release: ID:nGNE61LzBZ

Key Details


    MetricBeat/MissActualConsensus Estimate
    Q4 Revenue$10.40 mln
    Q4 Net Income-$26.32 mln
    Q4 Operating Income-$17.35 mln
    

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

    Recent news on Cellectis SA

    See all news